Vital Specialized Biopharmaceutical Insights and Analytics

for Experts from Experts

BioTrends is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.

Learn More

Featured Report
PatientTrends: Rheumatoid Arthritis US

Although there are many treatments available for RA, there is still a high unmet need for new treatments, especially for patients who are refractory to current therapies, such as TNF-alpha inhibitors, the most widely used biologic agents in RA...
Learn More

New Product 
ChartTrends: Wet Age-Related Macular Degeneration US

Age-related macular degeneration (AMD) is the leading cause of visual impairment and blindness in the United States, with vision loss occurring predominately in patients with the wet form of the disease. In order to better understand the actual treatment of wet AMD patients with anti-VEGF agents, the preferred treatment option, BioTrends Research Group is pleased to announce the upcoming publication of the inaugural ChartTrends: Wet Age-Related Macular Degeneration US report in June...
Learn More

Search Published Reports


See which reports have been searched on the most.



TreatmentTrends: Acute Kidney Injury (US) 2014

In this new report, both surveyed nephrologists and critical care physicians report that there is a high perceived need for new therapies for the treatment of acute kidney injury (AKI).


View sample slides from this report to learn more about our analysis of physicians’ practice patterns, attitudes and perceptions of projected use of various products in development for AKI.

Webinar on Demand

Tracking the Trial, Adoption and Usage of Xofigo

  • How does the launch of Xofigo compare with that of Zytiga and Xtandi?
  • What are surveyed medical oncologists’ current levels of awareness, familiarity and satisfaction with Xofigo, and how has this changed in the past six months?
  • To what extent is Xofigo currently being used among surveyed oncologists?
  • What are the perceived advantages and disadvantages relative to other currently available therapies for mCRPC?
  • What promotional messages are being employed by Algeta/Bayer HealthCare, according to surveyed medical oncologists?

Learn more!

Decision Resources Group brands include: